Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLIPSE: Atezolizumab Combinations in ER+/HER2- Breast Cancer
NCT03395899Phase 2
Key facts
- Status
- Completed
- Start
- Dec 2017
- Primary completion
- Aug 2023
- Countries
- 1
- Sponsor
- Queen Mary University of London
- Modality
- Small Molecules, Monoclonal Antibodies
- Conditions
- estrogen receptor-positive breast cancer (ER+)breast cancer
01
Overview
Phase 2, randomised, open-label trial of atezolizumab, cobimetinib, ipatasertib and bevacizumab in estrogen receptor-positive breast cancer (ER+) and breast cancer, sponsored by Queen Mary University of London. Started Dec 2017; status: completed.
02
Design
- Study design
- RandomizedOpen-label
03
Registry description
International, open label, window of opportunity phase II trial that aims to evaluate the effects of immunotherapy based treatment combinations in women with untreated, histologically confirmed, operable, ER+, HER2-negative breast cancer.
Beyond the preview
Go deeper on NCT03395899.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03395899.